
Plinabulin
CAS No. 714272-27-2
Plinabulin ( NPI-2358 )
产品货号. M15729 CAS No. 714272-27-2
Plinabulin (NPI-2358) 是一种抗微管蛋白解聚的血管破坏剂 (VDA),在肿瘤细胞中的 IC50 为 9.8~18 nM。阶段 1/2。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥267 | 有现货 |
![]() ![]() |
5MG | ¥421 | 有现货 |
![]() ![]() |
10MG | ¥624 | 有现货 |
![]() ![]() |
25MG | ¥1158 | 有现货 |
![]() ![]() |
50MG | ¥1871 | 有现货 |
![]() ![]() |
100MG | ¥2989 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Plinabulin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Plinabulin (NPI-2358) 是一种抗微管蛋白解聚的血管破坏剂 (VDA),在肿瘤细胞中的 IC50 为 9.8~18 nM。阶段 1/2。
-
产品描述Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.(In Vitro):Plinabulin (NPI-2358) (2-200 nM; 30 minutes; HUVECs cells) is a potent anti-tumor agent which is active in multidrug-resistant (MDR) tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs, with IC50 values of 18 nM for DU 145 cells; 13 nM for PC-3 cells; 14 nM for MDA-MB-231 cells; 18 nM for NCI-H292 cells; and 11 nM for Jurkat leukemia cells.(In Vivo):Plinabulin (0 mg/kg-15 mg/kg; intraperitoneal injection; female CDF1 and C3H/He mice) induces a time- and dose-dependent decrease in tumor perfusion. The KHT sarcoma is more sensitive than the C3H tumor to the anti-tumor effects of Plinabulin, while radiation response is enhanced in both models.
-
体外实验Cell Viability Assay Cell Line:HUVECs cells Concentration:2 nM, 10 nM, 20 nM and 200 nM Incubation Time:30 minutes Result:Low concentrations (2 nM, 10 nM) rapidly induced tubulin depolymerization in HUVECs.
-
体内实验Animal Model:Female CDF1 mice (10-14-week-old) with C3H mammary carcinoma; Female C3H/HeJ mice with KHT sarcoma cells (8-weeks-old)Dosage:0 mg/kg, 1.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 12.5 mg/kg, 15 mg/kg;0.02 mL/g mouse body weight in CDF1 mice and 0.01 mL/g body weight for C3H/HeJ mice Administration:Intraperitoneal injection; 0 huor, 1 huor, 3 hours, 6 huors, 24 huors Result:Induced a time- and dose-dependent decrease in tumour perfusion. The KHT sarcoma was more sensitive than the C3H tumour to the anti-tumor, while radiation response was enhanced in both models.
-
同义词NPI-2358
-
通路Cytoskeleton/Cell Adhesion Molecules
-
靶点Microtubule/Tubulin
-
受体Tubulin
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number714272-27-2
-
分子量336.39
-
分子式C19H20N4O2
-
纯度>98% (HPLC)
-
溶解度DMSO: 54 mg/mL warmed (160.52 mM)
-
SMILESO=C(/C(NC/1=O)=C\C2=CC=CC=C2)NC1=C\C3=C(C(C)(C)C)NC=N3
-
化学全称(3E,6E)-3-benzylidene-6-((5-(tert-butyl)-1H-imidazol-4-yl)methylene)piperazine-2,5-dione
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Nicholson B, et al. anticancer Drugs, 2006, 17(1), 25-3
产品手册




关联产品
-
Ixabepilone
一种半合成埃坡霉素 B 类似物和有效的口服活性微管稳定剂。
-
CCB02
CCB02 (CCB 02) 是 CPAP-微管蛋白相互作用的特异性小分子抑制剂,AlphaScreen 测定中 IC50 为 0.689 uM。
-
Sovilnesib
Sovilnesib 是一种驱动蛋白样蛋白 KIF18A 抑制剂 (WO2020132648)。 Sovilnesib 可用于癌症研究。